Table 3 Factors associated with VSP in patients treated with tocilizumab
Univariate Cox regression analysis | Multivariate Cox regression analysis | |||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age | 0.95 (0.90–1.01) | 0.090 | 0.95 (0.88–1.03) | 0.230 |
Sex | 2.00 (0.45–8.91) | 0.363 | ||
Disease duration | 0.97 (0.92–1.02) | 0.205 | ||
Naïve | 1.64 (0.62–4.30) | 0.316 | ||
Hypertension | 0.83 (0.11–6.32) | 0.856 | ||
Pulselessness | 1.07 (0.38–2.96) | 0.902 | ||
Vascular murmurs | 1.89 (0.70–5.13) | 0.212 | ||
Globin | 1.17 (1.04–1.31) | 0.012 | 1.04 (0.86–1.26) | 0.667 |
ESR | 1.02 (1.01–1.04) | 0.005 | 1.00 (0.96–1.04) | 0.965 |
CRP | 1.02 (1.01–1.03) | 0.006 | 1.01 (0.97–1.05) | 0.588 |
IL-6 | 1.02 (1.00–1.04) | 0.055 | 1.00 (0.96–1.05) | 0.910 |
IL-8 | 1.02 (0.98–1.05) | 0.412 | ||
C3 | 11.68 (1.86–73.4) | 0.003 | ||
C3 > 1.22 g/L | 9.17 (2.48–34.00) | 0.001 | 7.05 (1.50–33.07) | 0.013 |
C4 | 7.35 (0.04–1326.80) | 0.452 | ||
NIH score | 1.50 (0.77–2.91) | 0.235 | ||